press releases

Date Title Teaser
Date Title  
05/28/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET .
 
05/18/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
 
05/18/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen
 
05/14/20
Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent
 
05/13/20
Ide-cel, an investigational CAR T cell therapy for multiple myeloma, met primary endpoint and key secondary endpoints Pivotal study results demonstrated deep and durable responses in a heavily pre-treated and highly refractory patient population PRINCETON, N.J. , & CAMBRIDGE, Mass.
 
05/13/20
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc .
 
05/11/20
- Bristol Myers Squibb to buy out its ex- U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May 11, 2020 at 8:00AM ET –
 
05/11/20
- Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021 - - Completed submission with Bristol Myers Squibb of Biologics License Application (BLA) for anti-BCMA CAR T cell therapy idecabtagene vicleucel
 
05/08/20
-Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- bluebird bio, Inc.
 
04/29/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced it will hold a conference call to discuss first quarter 2020 financial results and business updates on Monday, May 11 at 8:00 am ET . Investors may listen to the call on May 11, 2020 at 8:00 am ET
 
03/31/20
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma PRINCETON, NJ . & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc
 
03/26/20
- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its
 
02/18/20
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positive
 
02/05/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference , Wednesday, February 26 , at 2:30 p.m.
 
01/13/20
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.